KRAS and colorectal carcinoma: Administration of R-IMPP to ApcMin/+KrasG12D/+Villin-Cre (50 mg/kg, i.p., 3 times/week) also significantly suppressed tumor number (P < 0.01) and load (P < 0.01) (Fig. S16), validating its efficacy in spontaneous APC/KRAS-mutant CRC.